
Pfizer buys Biohaven for $11.6 billion
The deal should put an end to the protracted M&A lull in the biotech sector.
Piper Sandler analyst Christopher Raymond also thinks so. He believes that the
Pfizer deal could restore sentiment about mergers and biotechnology in general.
The U.S. biotech sector experienced its worst April since